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Abstract
Aims: To establish the extent and impact of symptoms in 
patients with atrial fibrillation (AF), the importance of differ-
ent aspects of quality of life (QoL), and how we should assess 
wellbeing. Methods: Focus groups of patients with symp-
tomatic permanent AF in a trial of heart rate control; the 
RATE-AF trial randomised 160 patients aged ≥60 years with 
permanent AF and at least NYHA class II dyspnoea to either 
digoxin or beta-blockers. Patient and public representatives 
led the focus groups and performed all data acquisition and 
analysis, using thematic approaches to interpret patient 
views about QoL and its measurement. Results: Substantial 
impairment of health-related QoL was noted in 160 trial pa-
tients, with impact on all domains apart from mental health. 
Eight women and 11 men aged 61–87 years participated in 
the focus groups. Common themes were a lack of informa-
tion from healthcare professionals about AF, a lack of focus 
on QoL in consultations, and a sense of frustration, isolation, 
and reduced confidence. There was marked variability in 
symptoms in individual patients, with some describing se-
vere impact on activities of daily living, and profound inter-
action with comorbidities such as arthritis. Day-to-day varia-
tion in QoL and difficulty in attributing symptom burden to 
AF or other comorbidities led to challenges in questionnaire 
completion. Consensus was reached that collecting both 
general and AF-specific QoL would be useful in routine prac-
tice, along with participation in peer support, which was em-
powering for the patients. Conclusions: The impact of co-
morbidities is poorly appreciated in the context of AF, with 
considerable variability in QoL that requires both generic 
and AF-specific assessment. Improvement in QoL should di-
rect the appraisal, and reappraisal, of treatment decisions for 
patients with permanent AF. © 2020 The Author(s)
Published by S. Karger AG, Basel
Jacqueline Jones and Mary Stanbury are joint first authors.
This is an Open Access article licensed under the Creative Commons 
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Introduction
Atrial fibrillation (AF) is a major burden on patients 
and healthcare services. These effects are projected to in-
crease exponentially as our communities grow older and 
the incidence of AF in older people increases [1]. Al-
though adverse outcomes in AF such as stroke rightly re-
ceive attention from clinicians due to their preventable 
nature, poor patient quality of life (QoL) often lacks con-
sideration in clinical practice, despite also being amena-
ble to treatment.
Patients with AF have significantly poorer health-re-
lated QoL [2], which includes comparison with both 
healthy individuals and those with other cardiovascular 
diseases [3]. This has been attributed to the variety of 
symptoms that AF patients can suffer, including lethargy, 
palpitations, dyspnoea, sleeping difficulties, chest dis-
comfort, and psychosocial distress, as well as anxiety re-
lated to treatments and potential complications [4]. Al-
though QoL is significantly related to mortality, AF-relat-
ed symptoms do not necessarily track with clinical 
outcomes such as stroke, heart failure, or myocardial in-
farction, making extraction of QoL information impor-
tant for routine clinical management [5]. The majority of 
published studies on QoL in AF relate to the response to 
rhythm control therapies such as antiarrhythmic drugs or 
ablation. In contrast, patients with permanent AF have 
even worse QoL [6], account for around 50% of all pa-
tients, and yet we lack an adequate description of under-
lying factors [7].
The current unknowns about QoL in patients with 
permanent AF limit the scope of how effective clinicians 
can be in addressing patient concerns. We designed a 
qualitative study, led by a Patient and Public Involvement 
(PPI) team, and embedded within a clinical trial; the RAte 
control Therapy Evaluation in permanent Atrial Fibrilla-
tion (RATE-AF) trial [8]. Our aim was to explore 3 broad 
domains: (1) The perspective of patients on core compo-
nents of health-related QoL and how this is influenced by 
AF; (2) The measurement of QoL in AF and what tools 
were felt useful by patients to measure the response to 
treatment; and (3) Whether QoL was an important out-
come that clinicians should address.
Methods
This mixed methods study was part of the RATE-AF trial pro-
gramme, a prospective, open-label, blinded endpoint, randomised 
controlled trial of 160 patients with symptomatic permanent AF. 
The trial is the first to directly compare longer-term heart rate con-
trol using digoxin and beta-blocker therapy in this patient group 
(clinicaltrials.gov: NCT02391337, ISRCTN: 95259705, and Eu-
draCT: 2015-005043-13). The rationale and design of the study 
have previously been described [7]; in brief, the trial was embedded 
within the UK National Health Service (NHS), with minimal selec-
tion criteria to reflect routine clinical care. Patients were aged 60 
years or older, with permanent AF, in need of rate control, and 
breathlessness equivalent to at least New York Heart Association 
(NYHA) class II. As per guidelines, permanent AF was character-
ised as a physician decision for rate control with no plans for car-
dioversion, antiarrhythmic drugs, or ablation [9]. We only exclud-
ed patients with either clear requirements or contraindications for 
either drug, for example myocardial infarction in the last 6 months, 
a history of severe bronchospasm, bradycardia, or previous intol-
erance. The RATE-AF trial and the qualitative aspects were spon-
sored by the University of Birmingham and funded by the UK 
National Institute for Health Research (NIHR).
Patient and Public Involvement
A team of 3 PPI members helped to design and manage the 
trial, including positions on the Trial Steering Committee. The de-
sign of the focus groups was led by J.J. and M.S. from the PPI team, 
with the support of cardiology, patient-reported outcomes re-
search, and qualitative research teams at the University of Bir-
mingham. 
Participant Recruitment and Data Collection
Patients for the RATE-AF trial were recruited from referrals 
to 3 hospital sites in Birmingham (Queen Elizabeth Hospital, 
City Hospital, and Heartlands Hospital), and also directly from 
General Practices across the West Midlands region in the UK. As 
part of the consent procedure, all participants were asked if they 
could be contacted to contribute to the focus groups. From this 
cohort, 20 patients were consecutively invited to attend based on 
completion of all drug uptitration at that time (i.e., beyond the 
first 2 months of their trial participation), purposely sampled by 
gender and randomised group. No clinical variables were used to 
decide on focus group composition, but the participants had to 
be able to attend on the specified date (5 patients refused/were 
unable to attend on the date and were replaced with the next 
available patients). One patient who accepted was unable to at-
tend on the day due to illness. Focus groups were held at the 
NIHR/Wellcome Trust Clinical Research Facility at the Queen 
Elizabeth Hospital Birmingham in 2019 and split into 2 meetings 
for each arm of the trial. The first meeting focused on building 
rapport within the group and the impact of AF on their lives, with 
the second meeting focused on assessment and tools to measure 
that impact. Each meeting lasted approximately 2.5 h separated 
by two weeks (with a maximum of 10 participants in each meet-
ing). Focus groups were led by the patient and public representa-
tives (J.J. and M.S.) with D.K. also in attendance to address any 
medical issues.
Reimbursement
Every patient received a fixed sum of GBP 50 for their con-
tribution to each focus group, in addition to appropriate com-
pensation for travel and subsistence costs. PPI members re-
ceived funding according to NIHR INVOLVE guidance (https://
www.invo.org.uk/). There was no industry funding for any part 
of this trial. 
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QoL Tools
Three validated QoL questionnaires were used in the RATE-AF 
trial [7]. AF-specific QoL was assessed using the Atrial Fibrillation 
Effect on QualiTy-of-life (AFEQT) questionnaire [10]. Generic 
QoL was assessed using both the EuroQol EQ-5D-5L question-
naire [11] and the Short Form 36 Health Survey (SF36) [12]. The 
SF36 survey is comprised of eight domains; normalised UK values 
were taken from 8,889 respondents of a large-scale social survey, 
the Third Oxford Health and Lifestyles Survey (OHLS-III), sam-
pled from primary care in the UK [13]. t tests adjusted for unequal 
variance were used to compare mean values with data from the 
baseline visit of the RATE-AF trial. All participants of the focus 
groups had experience of completing all 3 questionnaires on at 
least 2 occasions during their trial visits. At the end of the first 
meeting, copies of the questionnaires were also provided to the 
participants for discussion at the next meeting.
Data Analysis
A topic guide was developed and finalised by the PPI team pri-
or to the focus groups, and this was used as a roadmap for discus-
sions in each meeting. The topic guide included specific questions 
relating to the three study domains and corresponding probe ques-
tions to explore these issues in more detail (online suppl. file; see 
www.karger.com/doi/10.1159/000511048 for all online suppl. ma-
terial). Audio recordings of the meetings were made with the con-
sent of all participants. A professional service transcribed the in-
terviews (clean verbatim), and the transcription was reviewed for 
consistency and accuracy by J.J. and M.S. The data (recordings and 
transcripts) were analysed using thematic approaches [14]. To or-
ganise the patient comments into the 3 key domains of interest, we 
developed a set of codes after the authors had familiarised them-
selves with the content of the transcripts. For the components of 
health-related QoL in AF, the codes related to any comment on: 
Physical impact from AF; Emotional impact from AF; Daily life im-
pact from AF; Impact on carers; Interaction with comorbidities; Pri-
or knowledge of AF or lack thereof; and Importance of QoL to the 
patient. For measurement of QoL in AF: Value of the QoL question-
naire; and Comparison of QoL questionnaires. For the importance 
of addressing QoL: Treatment expectations; Impact of the trial 
medications on physical function; and Impact of the trial medica-
tions on QoL. An iterative process was performed of coding each 
transcript (J.J. and M.S.). The codes were compiled in a data 
spreadsheet with extracted statements given primary codes (main 
issue raised by the patient in that comment) and secondary codes 
(where, if required, an additional issue was raised in the same com-
ment). J.J. and M.S. also manually extracted specific quotes from 
patients that were relevant or particularly significant to the group 
as a whole or may not have fitted into the specified codes.
Results
RATE-AF trial data at baseline from 160 patients 
with symptomatic permanent AF confirmed a substan-
tial reduction in QoL in all domains of the SF36 ques-
tionnaire, except for mental health. This was observed 
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Fig. 1. Comparative quality of life scores. SF36 quality of life scores in 160 RATE-AF patients. Left: Values com-
pared to the UK population average from the OHLS-III social survey in 8,889 participants. Right: Comparison 
with the 40% of respondents declaring a longstanding illness in OHLS-III. Higher scores indicate better quality 
of life; all components demonstrated statistically worse quality of life in RATE-AF patients (p < 0.0001), except 
for mental health (p = 0.49). 
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compared to the UK norm, as well as compared to those 
with a longstanding illness in population survey data 
(Fig. 1).
Nineteen participants took part in the focus groups, 
comprising 8 women and 11 men, all from a white British 
background. Mean age was 74 years (SD 7), with a range 
of 62–86 years. Patients had been diagnosed with AF for 
a mean of 5 years, and 10 (53%) had a known diagnosis 
of co-existing heart failure or signs of heart failure at base-
line. Other common comorbidities were hypertension in 
11 patients (58%), type 2 diabetes in 5 (26%), airways dis-
ease in 4 (21%), and previous stroke or transient isch-
aemic attack in 3 (16%). The demographics of the focus 
group participants were all comparable with the main tri-
al population [8]. All patients had completed uptitration 
of their trial medication (10 randomised to digoxin and 9 
to beta-blockers) and were on stable dosage with ade-
quate control of heart rate. A summary of key findings, 
determined by the Patient and Public leads, is presented 
in Figure 2 and a summary for patients in Figure 3.
Domain 1
Determinants of QoL in Patients with AF
Key issues raised with regards to determinants of QoL 
and how AF affects the lives of patients were:
1 There was consistent feedback about a lack of informa-
tion from healthcare professionals about AF and a lack 
of focus on QoL in healthcare consultations. This led 
to a sense of frustration, isolation, and reduced confi-
dence which contributed to the overall impact of AF 
on patient wellbeing. 
2 The impact of AF was not just felt by patients, but also 
by their primary caregivers and the wider family. 
3 There was marked variability in AF symptoms in indi-
vidual patients, with some describing severe impact on 
physical capacity and activities of daily living due to 
breathlessness, fatigue, and dizziness, whereas others 
had few symptoms. 
Impact not just on patient, but also family/ 
carers, made worse by lack of information
Substantial individual variability in physical 
consequences from AF
Major lifestyle changes required after AF 
diagnosis
Large burden of comorbidities which 
interacted with AF symptoms
Considerable day-to-day variability, hence 
challenging to complete questionnaires 
Partner/carer often disagreed with the 
answer given by the patient
Difficult balance of complex forms like SF36 
compared to simplistic scales like EQ-5D-5L
Need for both generic and AF-specific 
questionnaires to capture total AF impact
In patients with permanent AF, 
improvement in QoL was paramount
Medications for AF should be regularly 
reviewed in the context of QoL 
A focus on QoL can lead to patient 
empowerment and better self-care
More widespread use of patient support 
groups could improve confidence and QoL
(Domain 1)
Determinants
of QoL
in patients
with AF 
(Domain 2)
Measurement
of QoL
in patients
with AF 
(Domain 3)
Importance
of QoL
for AF
management
Fig. 2. Summary of RATE-AF focus groups. Key issues raised by 
patients according to relevant themes. AF, Atrial fibrillation; QoL, 
Quality of life.
Does atrial fibrillation (AF) affect a patient’s quality of life? 
• How severely patients are affected by AF varies a lot
• Other health problems can influence how AF affects each person
• Coping with AF often requires changes in daily living
• AF has an impact on the patient, but also affects their family and carers
How might patients feel because of AF? 
• Patients may have different feelings from day to day
• What a patient feels may not agree with what their family or carer sees 
• Whether these feelings are due to AF, or other health conditions, is 
different for every patient
• We need more research to find better ways to measure how patients 
are feeling. 
Is it important to know how patients with AF are feeling? 
• Patients with AF in this study were keen to improve their quality of life
• It can be useful to monitor how quality of life changes in response to 
treatment
• Patients monitoring how they feel can have a positive effect on their 
quality of life
• AF support groups can help patients to feel confident and enjoy a 
better quality of life
Fig. 3. Summary for patients. Information about atrial fibrillation 
(AF) for patients can be found at: https://www.bhf.org.uk/infor-
mationsupport/conditions/atrial-fibrillation. Patient resources 
and support are available at: https://www.heartrhythmalliance.
org/afa/uk/for-patients.
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4 In group discussion, the patients concluded that the 
impact of comorbidities (especially large-joint arthri-
tis) was the most important determinant of the effect 
of AF on physical activity. There was consistent feed-
back that the effect and treatment of comorbidities was 
poorly considered in interactions with healthcare pro-
fessionals.
5 Adaptation to a new style of living was required after 
the diagnosis and treatment of AF, and there were con-
siderable emotional impacts.
A summary of quotes from patients relevant to this 
domain are presented in Table 1. 
Domain 2
Measurement of QoL in Patients with AF
The key points discussed about tools to measure QoL 
and treatment response were:
1 Most patients found it difficult to complete question-
naires due to considerable day-to-day variation in 
their AF-related symptoms. There were challenges for 
questionnaires like EQ-5D-5L (which asks about im-
pact today), as well as SF36 and AFEQT (4-week recall 
period). 
Table 1. Determinants of QoL in patients with AF
Impact Quote Comments/Context
Emotional impact on 
patient and family
“As you say it can be a lonely thing [having AF]; You’ve got 
company round you but even so, you are thinking am I the 
only one like this?”
“I’m losing my confidence to go out.”
“If you aren’t positive you might as well pack up and sit in 
your armchair.”
“Unfortunately, my partner takes the brunt in the way I 
sometimes feel [anger and frustration].”
“I find the most exasperating thing is having to ask for help; 
I loathe it.”
“I sometimes think I don’t go anywhere where I’m more 
than half an hour away from [the hospital], because it’s 
frightening if something does go wrong.”
Common feelings were fear and bewilderment at the time of 
diagnosis, which persisted.
Consistent theme of inability or reticence to ask questions leading 
to a loss of confidence; often not verbalised to their usual 
healthcare practitioners.
General feelings of isolation, with a sense of loneliness that was 
pervasive despite interaction with family and friends.
Dependency and burden on caregivers was highlighted many 
times.
Fear of complications and the unknown was common, and 
impacted on overall QoL.
Impact on physical 
activity
“If I’m out on a walk and come to a hill it gets harder and 
harder and I get slower and slower.”
“I used to play rugby and cricket, but walking round the 
snooker table [is all I can manage] and I don’t know 
whether that counts [as exercise].”
“I feel a bit of a fraud because I have no symptoms; I walk 
2.5 miles every day to get my paper, and I don’t just walk, I 
pound it.”
“Housework and stuff – I can’t do what I used to do. When 
vacuuming sometimes I stop after five minutes and I’m 
breathless and [need to] sit down.”
“I can do my housework slowly and everything seems fine.”
“My life is so changed following [AF therapy] – I can walk 
and I’m a garden fanatic; I’m out there digging and sawing 
trees.”
There was a diverse range of comments on the impact of AF on 
physical capabilities.
The majority of patients felt that their AF had negatively 
impacted on physical activity, but a few patients had no apparent 
change in their ability; a minority recognised an increase in their 
ability to carry out physical activity due to medical therapy for 
previously undiagnosed AF.
The uncertainty of not knowing how they would feel on any 
given day was frustrating, particularly as causal factors were 
difficult to identify (i.e., whether due to AF, comorbidities, the 
general aging process, or a combination).
The impact of emotional factors on physical activity was evident, 
particularly anxiety around their AF diagnosis, and the effect on 
their cardiovascular and general health.
Impact on daily living 
and wellbeing
“I feel degraded my wife has to shower me.”
“I was full of life, but no longer.”
“[I am] breathless and have no energy to stand there and do 
it [ironing].”
“Previous lifestyle has now completely changed.”
“I force myself to do things. You can’t just sit in the chair all 
day looking out of the window.”
For a few patients, there was little change in daily living, but the 
majority felt that their AF diagnosis had a major effect on daily 
wellbeing.
Living with the variability of symptoms on a daily basis created 
uncertainty for patients around being able to plan activities; there 
was a sense that on any given day their body would dictate the 
amount of activity they were able to undertake.
Asked to rate the impact of AF on their daily life (where 1 was no 
impact and 10 the greatest impact), the majority gave a score of 7 
or above.
Some patients acknowledged that their previous lifestyle was not 
compatible with their current status after the diagnosis of AF; the 
realisation that significant changes were required in their daily 
planning was found to be extremely hard to accept and to adapt.
Jones et al.Cardiology6
DOI: 10.1159/000511048
2 Separation of emotional from physical wellbeing (for 
example in SF36) was confusing for many patients 
who felt that AF impacts were inter-related. 
3 AFEQT had the most relevance to AF symptom bur-
den, but attribution to AF or other comorbidities was 
challenging.
4 There was a difficult balance to strike between content 
and time taken; for example, comparing the brevity of 
the EQ-5D-5L questionnaire with the more nuanced 
but also potentially duplicating questions in SF36. 
5 Consensus that collecting both generic and AF-spe-
cific QoL would be useful in clinical practice to help 
clinicians understand the patient’s perspective; on 
balance, the group favoured using EQ-5D-5L with 
AFEQT.
A summary of relevant quotes from patients relating 
to each of the 3 QoL tools are presented in Table 2. 
Domain 3
Importance of QoL in the Management of Patients 
with AF
The major discussion points raised in the focus groups 
as to whether QoL was an important outcome that clini-
cians should address were:
1 Improvement in QoL was the most important consid-
eration for this patient group, ahead of mortality or the 
need for hospital visits.
2 Healthcare professionals in prior consultations often 
prioritised issues that were important to them rather 
than the patient, such as deciding on stroke prevention 
or rhythm control treatments, or on a specific target 
for heart rate control. 
3 A lack of medication review in patients on longstand-
ing treatments contributed to worse QoL and emo-
tional/physical impact from AF. 
Table 2. Measurement tools for QoL in AF
Tool Quote Comments/Context
SF36 “Often I felt [my symptoms] fell between two tick boxes.”
“When you actually fill it in, it gives you time to think of what you 
felt like. It can be the mood you’re in.”
“My partner coaxed me into answering, and I said do you agree with 
what I am saying? She responded with: No, I don’t agree with that.”
“Pigeonholing [how I feel] into the right box that most accurately 
describes how I feel about my AF symptoms is difficult.”
“I think if I’ve got AF and there’s a risk of a stroke [so] how can I put 
my health down as good?”
“I think there’s a lot of duplication… are you worn out? Have you 
felt downhearted? Are you full of energy?”
There was a general consensus within the group that a diagnosis 
of AF led to symptoms and activity limitation that varied from 
day to day, making it challenging to average QoL over a four-week 
period.
Participants commented it was good to have time for reflection 
when completing the questionnaire; it provided them with the 
opportunity to see both positive and negative aspects of their 
general health and wellbeing in the context of their AF diagnosis.
The perceptions of the carer/partner were not necessarily in 
agreement with the patient when completing the questionnaire.
The duplication of questions was raised repeatedly, leading to 
concern about validity from the patients.
EQ-5D-5L “With this questionnaire I want to write on everything: ‘Yes, but this 
has nothing to do with my AF’. But how is this going to be 
interpreted, what use will it be, and am I screwing this up by filling 
this in this way?”
“I have no problem filling it in, but separating AF symptoms from 
other health problems is difficult.”
“You can come up with different answers within minutes, let alone 
today, tomorrow, and the next week”
“I don’t know which [symptoms] belong to AF and I don’t know 
which ones belong to the other problems I have.”
Consensus was reached that this questionnaire would be useful 
alongside AFEQT in clinical practice to provide more accurate 
feedback to healthcare staff on general health.
The brevity of the questionnaire was favoured, but some patients 
felt it difficult to sum up their wellbeing for that particular day.
As with the other questionnaires, the issue of separating 
comorbidities and the general aging process was problematic.
Transient symptoms created difficulty when completing the 
questionnaire.
AFEQT “The questions asked provided reassurance that my symptoms are 
not just about the aging process.”
“It makes you realise, it’s not you, it’s just part of you that the AF is 
doing all these to you.”
“Filling in the questionnaire covering four weeks is difficult. Some 
mornings I can get up and feel fine then two hours later I feel yuck.”
“How do I answer [whether I am bothered]? Is it that I am not 
bothered at all because it’s there, or I’m very bothered because it 
worries me?”
“Awkward questions for me… is it [due to] my medication or is it 
just generally how I am [with my AF]?”
The group were unanimous in their agreement that this 
questionnaire was easier to complete than SF36, and it gave the 
opportunity for informed choices within their answers.
The scale of being “bothered” created difficulty with participants 
being unsure how to interpret their anxieties around their AF 
diagnosis and the resultant symptom burden.
AFEQT does not encompass general health, which in some 
patients had a bigger impact on overall QoL.
Confusion around symptoms being a result of medications for AF 
or other comorbidities (e.g., breathlessness due to asthma).
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4 A focus on QoL improvement could engage patients 
leading to empowerment. The integrated approach in 
the RATE-AF trial of providing patient education and 
support was unanimously well received by patients in 
the focus groups who expressed a sense of confidence 
and better ability to self-manage their AF.
5 Participation in the focus group itself was beneficial 
for the patients, who recommended a similar process 
of peer-support for patients newly receiving treatment 
for AF, for example, after discharge from hospital.
A summary of relevant quotes from patients are pre-
sented in Table 3; in general, these reflect a mixture of the 
psychosocial and physical impacts of AF, coping mecha-
nisms, and outcomes related to these effects. Whilst this 
study cannot address whether attention to QoL would 
improve clinical outcomes, there was consensus from pa-
tients that it could improve the care pathway in patients 
with AF.
Discussion
This study confirmed that patients with symptomatic 
permanent AF have considerably worse QoL than the 
general population or those with a longstanding illness. 
In focus groups, QoL and symptom management were 
the predominant concerns of these patients. The wide 
variation in symptoms experienced, both generic and AF-
specific, were underscored by a substantial emotional 
burden on patients and their families. A reported lack of 
focus on QoL in prior healthcare consultations contrib-
uted to a loss of confidence and a sense of isolation that 
hindered medical management of their condition. Fur-
ther, patients felt that the extent of their comorbidities 
was often neglected. To improve patient wellbeing, man-
agement protocols need to consider other conditions 
such as large-joint arthritis, and not just concentrate on 
anticoagulation therapies for AF.
Table 3. Importance of QoL for management of AF
Topic Quote Comments/Context
Ranking of 
outcomes
“If we’re talking about AF, [the important factor] is quality of life and to be as 
symptom free as we can; to live each day in a way to our maximum potential, 
whatever age we are and whatever else we’ve got, but being able to do life to our 
maximum.”
“It would be nice for the doctors to ask what is the quality of your life, how is 
this affecting the quality of your life.”
“I want a longer life and a better quality of life.”
“A focus [on QoL] definitely had a positive impact… I don’t get out of breath 
like I was six months ago.”
QoL consistently rated as the most important 
outcome in these focus groups.
Patients were less concerned about other 
outcomes, such as hospital admissions, which were 
usually considered as well-managed by healthcare 
professionals.
Specific questions from healthcare professionals 
about the impact of AF on QoL was rare.
Patient 
empowerment
“When you go to bed of a night and you think to yourself ‘well, I had a good day, 
I enjoyed reading that book,’ or ‘at least I cleaned the stove, I did it with a little 
mop’. It’s ridiculous but that’s it, you go to bed [and] tomorrow is another day. 
If I wake up, I’ll see what else I can do.”
“I remember standing when I was out of breath, looking in shops and 
pretending; I remember a man said to me one day ‘You’re out of breath’ [and I 
said] ‘No, I’ve got a bad back’. I was so embarrassed to say I was out of breath… 
and it was to do with my heart.”
“When you’re feeling breathless you step back and stop. [But now] I just push it 
that little bit further, and a little bit further, and I felt that has really helped.”
Uncertainty around living with AF, and the 
variability in day-to-day symptoms increased the 
importance of attention on QoL.
Lack of knowledge and fear of the unknown had a 
negative impact on patients.
Being provided with broader education (such as 
safely increasing exercise to work through 
breathlessness) was transformative for 
empowering patients.
Treatment 
expectations
“I don’t expect a miracle, but I would like to think that the quality of life I will 
have will be better because of [medications I take].”
“I’ve been on the same medication for ten years; I’ve come [on this trial] and I’ve 
had a change… looked at thoroughly and properly, and now I feel so much 
better.”
“I could not have carried on living the life I was living.”
“Having been on the trial, it gives you more reassurance that you’re dealing with 
people who are interested in AF, and I think it makes you more reassured, gives 
you more confidence I think. I’m happier.”
“I was so tired. But [now] that seems to have gone, so that’s better quality of life, 
and it’s fantastic.”
“I want to be treated as a person not just as an AF [patient]; I want the whole 
thing treated.”
“It helps when you know somebody else is going through it.”
Although doctors give medications in AF for 
specific purposes (e.g., drugs to control heart rate), 
the expectation from patients is that these will 
improve QoL.
In patients with longstanding AF, patients felt that 
they were left without clinical attention; a 
refocused appraisal of medications in the context 
of QoL could be helpful at regular reviews.
Prior consultations mostly focused on stroke 
prevention and oral anticoagulation.
Being able to discuss the impact of AF with other 
patients in a supported group improved 
confidence in self-management.
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There is increasing recognition that QoL and symp-
tom data should be collected in routine clinical practice 
for patients with AF [15]; however, measurement of QoL 
in patients with AF is associated with a number of meth-
odological challenges. In a systematic review of measure-
ment properties for AF-specific QoL tools, we identified 
substantial validity concerns for commonly used ques-
tionnaires [16]. Hence, many research studies have used 
generic QoL tools, such as SF36 and EQ-5D-5L. Whilst 
generic questionnaires allow for comparison across dif-
ferent diseases, they lack attention on the types of symp-
toms that can impair QoL in patients with AF. In our fo-
cus groups, there was consensus amongst patients that a 
short generic tool, such as EQ-5D-5L, in addition to an 
AF-specific tool, such as AFEQT, provided the best bal-
ance of time taken versus information gained. Although 
SF36 is comprehensive, and from a technical standpoint 
appears to cover many of the concepts discussed by pa-
tients, there was concern around difficulty to separate 
emotional and physical impacts from AF, the need for 
questions to be explained by clinical staff, and duplication 
in responses. An added advantage of EQ-5D-5L is the use 
within health economics such as quality-adjusted life-
year (QALY) analyses. Whichever QoL tool is chosen, our 
patient groups were clear that they could see a potential 
benefit in rolling-out these questionnaires into routine 
clinical practice. Not only would this give patients a 
framework for their consultations with healthcare profes-
sionals, but it would also allow staff to monitor changes 
in QoL in response to treatment. 
Consideration of patient-reported outcomes is now 
part of international practice guidelines on AF manage-
ment; clinicians are asked to assess and re-assess QoL, 
with symptomatic improvement a major treatment ob-
jective in patients with AF [9]. Aside from oral antico-
agulation for stroke prevention, nearly all other treat-
ments (including rate and rhythm control) are based on 
evaluation of symptoms. More research on assessment of 
QoL in clinical practice is clearly warranted to inform 
clinical decision making and to tailor care to the needs of 
individual patients. Electronic capture of these data in 
routine practice could allow for real-time monitoring, 
flexible and responsive scheduling of hospital appoint-
ments, early detection of problems, and prompt interven-
tion to prevent AF-related adverse outcomes [17]. Atten-
tion on comorbidities is also an essential component for 
optimal management of AF. In the RACE III trial, 245 
patients with early persistent AF and mild-to-moderate 
heart failure were randomised to either targeted therapy 
of underlying conditions or normal care including rhythm 
control [18]. Comorbidities were better treated in the in-
tervention group and recurrence of AF was lower (75% of 
all patients were in sinus rhythm at 1 year, compared to 
63% in the conventional management group; p = 0.042). 
Similarly, integrated treatment programmes that im-
prove patient and healthcare staff education, along with 
nurse-led and lifestyle interventions, have demonstrated 
improvements in clinical outcomes. In a randomised tri-
al of 712 patients with AF, integrated care led to better 
adherence to guidelines [19]. The composite of cardio-
vascular hospitalisation and cardiovascular death was sig-
nificantly lower in the integrated care arm, 14.3% com-
pared with 20.8% with usual care (hazard ratio 0.65; 95% 
CI 0.45–0.93; p = 0.017). Bringing together patients and 
their healthcare professionals in order to make shared de-
cisions is a key element in patient empowerment [9], es-
pecially in this digital era [20], and has the potential to 
address the persistently poor outcomes seen in older pa-
tients with AF [1]. Randomised trials to clarify the impact 
of AF education for healthcare professionals are ongoing 
[21]. As demonstrated in a mixed-methods study of 101 
patients and 15 clinicians, a lack of appropriate education 
also hinders the ability of patients to self-manage their AF 
[22]. The importance of a good knowledge-base has been 
studied previously, mostly in the context of anticoagula-
tion for stroke prevention [23]. Our impression is that 
education on other aspects of care, for example, heart rate 
control, is often neglected in clinical practice. This is par-
ticularly the case for patients with permanent AF, who 
often receive no other therapy and are, therefore, left 
without the support that patients with paroxysmal AF 
typically receive when considered for rhythm control. 
An unexpected outcome from the focus groups was 
the benefit the groups themselves had for individual pa-
tients. Having a safe space to talk to other patients led to 
amelioration of the sense of isolation and lack of knowl-
edge. As with other chronic diseases, many of the impacts 
of AF are psychosocial in nature, and so better adaptation 
can be a powerful tool (a clear, cross-cutting theme across 
the domains we investigated). More widespread use of 
patient support groups within secondary care could have 
profound benefit for patients and lead to reductions in 
healthcare utilisation. For example, in hospitalised pa-
tients, accredited information could be provided to all pa-
tients before, during, and after discharge, along with de-
tails of a national or local patient organisation for infor-
mation and emotional support. Local patient support 
groups are run by charities such as the Arrhythmia Alli-
ance and AF Association (https://www.heartrhythmal-
liance.org/), who also moderate online forums with thou-
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sands of members, organise Patient Educational Days, 
and provide dedicated helplines. Close partnership with 
these organisations has the potential to support patients 
and their carers, and further enhance health-related QoL 
in those with AF [24]. 
Strengths and Limitations
All included patients had permanent AF with symp-
tom-related impairment of daily life at baseline (NYHA 
class II or above); hence the results presented reflect this 
patient group. The focus groups took place after control 
of heart rate and symptoms to better represent the broad-
er community with managed permanent AF. We are lim-
ited by the number of patients involved and the need to 
provide depth over breadth of concepts. Greater num-
bers within each focus group would have limited discus-
sion, and hence each meeting was restricted to 10 pa-
tients. We divided the sessions into two segments to 
avoid overloading the participants. Meetings were of suf-
ficient duration to achieve saturation within each do-
main, and they were undertaken within a few weeks of 
each other to minimise any change over time. All meet-
ings were scheduled in a comfortable and secluded area 
of the hospital research unit, well known to the patients 
to limit anxiety. Our analytical methodology used the 
broad concept of thematic analysis, with a pragmatic ap-
proach to reflect that patient and public representatives 
were leading the focus groups, coding transcripts, and 
providing data analysis. This provided a unique insight 
into patient views at many levels. Although the included 
patients were typical of those with permanent AF and 
symptom-related impairment of daily life treated in rou-
tine clinical practice, we cannot exclude distinct themes 
arising within patients that agreed to contribute to the 
focus groups. Those that participated may place a differ-
ent value on the importance and subsequent assessment 
of QoL. However, the main discussion points raised in 
this research were similar in both of the randomised 
treatment arms, which underwent separate focus group 
meetings. Our findings would not necessarily apply to 
AF patients of other ethnic backgrounds, as there are 
known differences in the presentation and outcomes of 
AF amongst different racial groups [25].
Conclusion
Assessing and measuring improvement in QoL and 
symptoms is fundamental to better management of pa-
tients with permanent AF, who suffer from a substantial 
reduction in their physical wellbeing. The impact of co-
morbidities is poorly appreciated, with considerable vari-
ability in QoL requiring both generic and AF-specific as-
sessment. Broader education is required beyond what is 
typically given around the prevention of stroke. More 
widespread use of questionnaires and peer support could 
have benefits in patients with AF seen in routine clinical 
practice, enabling care to be tailored to their individual 
needs.
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